What is HC Wainwright’s Forecast for RIGL Q3 Earnings?

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) – Analysts at HC Wainwright issued their Q3 2025 earnings per share (EPS) estimates for shares of Rigel Pharmaceuticals in a report issued on Wednesday, March 5th. HC Wainwright analyst J. Pantginis anticipates that the biotechnology company will earn $0.34 per share for the quarter. HC Wainwright currently has a “Buy” rating and a $57.00 target price on the stock. The consensus estimate for Rigel Pharmaceuticals’ current full-year earnings is $0.22 per share. HC Wainwright also issued estimates for Rigel Pharmaceuticals’ Q4 2025 earnings at $0.48 EPS.

Other research analysts have also recently issued research reports about the company. Citigroup lifted their target price on Rigel Pharmaceuticals from $40.00 to $49.00 and gave the company a “buy” rating in a research report on Tuesday, November 12th. StockNews.com cut Rigel Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Thursday, February 27th. Piper Sandler boosted their price objective on Rigel Pharmaceuticals from $15.00 to $23.00 and gave the stock a “neutral” rating in a research report on Thursday, November 14th. B. Riley boosted their price objective on Rigel Pharmaceuticals from $20.00 to $24.00 and gave the stock a “neutral” rating in a research report on Wednesday. Finally, Cantor Fitzgerald boosted their target price on Rigel Pharmaceuticals from $15.00 to $25.00 and gave the company a “neutral” rating in a research note on Tuesday, December 10th. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat, Rigel Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $35.60.

Rigel Pharmaceuticals Price Performance

Shares of RIGL opened at $20.29 on Thursday. The company has a market capitalization of $357.41 million, a price-to-earnings ratio of 144.94 and a beta of 1.35. The business has a 50-day moving average of $20.01 and a 200-day moving average of $18.40. Rigel Pharmaceuticals has a 1 year low of $7.48 and a 1 year high of $29.82.

Rigel Pharmaceuticals (NASDAQ:RIGL) last announced its quarterly earnings results on Tuesday, March 4th. The biotechnology company reported $0.80 EPS for the quarter, beating analysts’ consensus estimates of $0.30 by $0.50. Rigel Pharmaceuticals had a negative return on equity of 14.80% and a net margin of 2.46%. The firm had revenue of $57.60 million for the quarter, compared to analyst estimates of $57.59 million.

Institutional Trading of Rigel Pharmaceuticals

Large investors have recently modified their holdings of the company. PDT Partners LLC bought a new stake in Rigel Pharmaceuticals during the third quarter valued at about $322,000. Los Angeles Capital Management LLC grew its holdings in Rigel Pharmaceuticals by 34.5% during the third quarter. Los Angeles Capital Management LLC now owns 74,502 shares of the biotechnology company’s stock valued at $1,205,000 after purchasing an additional 19,094 shares during the period. Connor Clark & Lunn Investment Management Ltd. grew its holdings in Rigel Pharmaceuticals by 29.7% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 98,006 shares of the biotechnology company’s stock valued at $1,586,000 after purchasing an additional 22,443 shares during the period. Barclays PLC boosted its stake in shares of Rigel Pharmaceuticals by 158.6% in the third quarter. Barclays PLC now owns 27,345 shares of the biotechnology company’s stock worth $442,000 after acquiring an additional 16,772 shares during the period. Finally, JPMorgan Chase & Co. boosted its stake in shares of Rigel Pharmaceuticals by 45.0% in the third quarter. JPMorgan Chase & Co. now owns 26,238 shares of the biotechnology company’s stock worth $425,000 after acquiring an additional 8,140 shares during the period. Institutional investors own 66.23% of the company’s stock.

Insider Buying and Selling at Rigel Pharmaceuticals

In other Rigel Pharmaceuticals news, CFO Dean L. Schorno sold 2,036 shares of the stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $20.92, for a total transaction of $42,593.12. Following the sale, the chief financial officer now directly owns 58,969 shares in the company, valued at approximately $1,233,631.48. This trade represents a 3.34 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Raul R. Rodriguez sold 4,952 shares of the stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $20.92, for a total value of $103,595.84. Following the sale, the chief executive officer now owns 243,854 shares in the company, valued at approximately $5,101,425.68. This represents a 1.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 9,113 shares of company stock worth $190,644. Insiders own 9.04% of the company’s stock.

About Rigel Pharmaceuticals

Rigel Pharmaceuticals, Inc, a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company’s commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer.